<meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><!DOCTYPE doctype html>
<html class="Unknown 0_0 Unknown Unknown titanDisplay" id="htmlTag" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <link href="/ClientCss/style_eperc.css" rel="stylesheet" type="text/css"/>
  <meta content="Titan CMS" name="creator"/>
  <title id="pageTitle">
   # 116 Radiopharmaceuticals for Painful Osseous Metastases
  </title>
  <meta content="72581" name="DocID">
   <meta content="# 116 Radiopharmaceuticals for Painful Osseous Metastases" name="Title">
    <meta content="# 116 Radiopharmaceuticals for Painful Osseous Metastases, Medical Knowledge, Pain – Non-Opioids, Patient Care" name="Keywords">
     <meta content="" name="Description">
      <meta content="" name="Abstract">
       <link href="/display/WhatsNew.rss" rel="alternate+rss" title="RSS" type="application/rss+xml"/>
       <script src="/Scripts/titanscripts.js" type="text/javascript">
       </script>
       <script src="/Scripts/Banner.js" type="text/javascript">
       </script>
       <script src="http://www.google.com/recaptcha/api/js/recaptcha_ajax.js" type="text/javascript">
       </script>
       <script src="/commonScripts/mcwCommon.js" type="text/javascript">
       </script>
       <script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
       </script>
       <script type="text/javascript">
        try {
var pageTracker = _gat._getTracker("UA-11124256-1");
pageTracker._trackPageview();
} catch(err) {}
       </script>
      </meta>
     </meta>
    </meta>
   </meta>
  </meta>
 </head>
 <body class="titanBody" id="bodyTag" onclick="if (window['TitanClickHandler']) TitanClickHandler(this, event)" onload="TitanLoad();">
  <form action="/EPERC/FastFactsIndex/ff_116.htm?" enctype="multipart/form-data" id="routerForm" method="post" name="routerForm">
   <input id="__VIEWSTATE" name="__VIEWSTATE" type="hidden" value="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"/>
   <script src="/ScriptResource.axd?d=xFDxeqDolrWHepB5BOa6WusqXFLn3wro2JYAUSW54WCZIM7tlRS9tbqUciiQ66IHFJNcNWN3CVU9VVXPPRcSENg7qOCQHN4cE4-dXQ8bxlvvzOwDdwbXgIu1gG27qPOQ1CQrIgFe_q5BlrAijrvDUgIWykSGToLqgYeMH1AtHUs1&amp;t=ffffffff940d030f" type="text/javascript">
   </script>
   <script src="/display/components/Blocks/Commenting/Support/CommentingAjax.asmx/js" type="text/javascript">
   </script>
   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
       <div id="titleBarContainer">
        <h1>
         # 116 Radiopharmaceuticals for Painful Osseous Metastases
        </h1>
       </div>
       <!--/titleBarContainer -->
       <div blockinfo="Freeform CenterZone BlockID1" class="Freeform CenterZone BlockID1">
        <h4>
         <strong>
          <a href="./ff_116.htm" linktype="4" target="_blank">
           FAST FACTS AND CONCEPTS #116 PDF
          </a>
         </strong>
        </h4>
        <p>
         <br/>
         <b>
          Author(s):
         </b>
         Gary M Reisfield MD and George R Wilson MD
        </p>
        <p>
         <b>
          Introduction
         </b>
         This Fast Fact reviews bone-seeking radiopharmaceuticals (radionuclides), which occupy a valuable niche in the palliation of painful bone metastases (see
         <a href="./ff_066.htm" linktype="4" target="_blank">
          Fast Facts #66
         </a>
         and
         <a href="./ff_067.htm" linktype="4" target="_blank">
          67
         </a>
         for a general discussion of palliative radiation).
        </p>
        <p>
         <b>
          Isotopes and Physiology
         </b>
         The three isotopes available in this country –
         <sup>
          89
         </sup>
         Sr (strontium-89),
         <sup>
          153
         </sup>
         Sm (samarium-153), and
         <sup>
          32
         </sup>
         P (phosphorus-32) – work by binding with high affinity to hydroxyapatite in regions of rapid bone turnover near osteoblastic metastases, delivering therapeutic doses of localized beta radiation, with a tissue penetration measured in millimeters. The precise mechanism of analgesia is unknown but is probably not dependent solely on cell kill. Rather, analgesia may also be a function of inhibition of lymphocyte-associated cytokines or alterations in osteoclast and/or osteoblast activity.
        </p>
        <p>
         <b>
          Benefits
         </b>
         Analgesia may begin within 3-7 days, but more typically begins within one to two weeks after administration. Analgesia will last from two to six months; treatment may be repeated. Symptom improvement is noted in 60-80% of patients, with complete analgesia in 20-30% of responders. Radiopharmaceuticals may delay onset of pain in pre-existing, clinically silent metastases.
        </p>
        <p>
         <b>
          Procedure
         </b>
         The radiopharmaceutical is delivered in the outpatient setting by a single IV injection or orally (
         <sup>
          32
         </sup>
         P only). Administration requires no special monitoring.
        </p>
        <p>
         <b>
          Patient selection
         </b>
         Patients with multiple painful bone metastases, demonstrated by bone scan and/or plain X-ray, corresponding to site(s) of pain and an expected survival of &gt;12 weeks are appropriate for radiopharmaceutical therapy. Evidence supporting efficacy in prostate and breast cancer is substantial; data for other tumor types are limited.
        </p>
        <p>
         <b>
          Contraindications
         </b>
        </p>
        <ul>
         <li>
          Preexisting myelosuppression (e.g. WBC &lt;3.0K and Platelets &lt;60-100K).
         </li>
         <li>
          Oncological urgencies/emergencies in which radiopharmaceuticals will be of no benefit (e.g. actual or impending spinal cord compression or pathologic fracture).
         </li>
         <li>
          Renal insufficiency (relative contraindication).
         </li>
         <li>
          Evidence of disseminated intravascular coagulation (relative contraindication).
         </li>
         <li>
          Pregnancy
         </li>
        </ul>
        <p>
         <b>
          Adverse effects
         </b>
        </p>
        <ul>
         <li>
          Marrow suppression: Reversible, moderate neutropenia and thrombocytopenia – manifested by approximately 30-70% drop in leukocyte and platelet counts – is a predictable side effect. Depending on the specific agent this begins two to four weeks following administration, with a nadir between weeks four to six. Bone marrow recovery occurs by weeks eight to twelve.
         </li>
         <li>
          Pain flare: Increasing pain occurs in 10-20% of patients, usually within the first week of administration. It is transient and may be predictive of a good therapeutic response.
         </li>
        </ul>
        <p>
         <b>
          Approximate retail costs (Note: dosing is calculated based on patient weight.)
         </b>
        </p>
        <ul>
         <li>
          Strontium-89 chloride injection: $3,097 / 5 mCi.
         </li>
         <li>
          Samarium-153 lexidronam injection $2,770 / 150 mCi.
         </li>
         <li>
          Sodium phosphate P-32 solution: $500 / 5 mCi.
         </li>
        </ul>
        <p>
         <b>
          Comparative Data
         </b>
         There is little data comparing the three agents. However, the International Atomic Energy Agency sponsored a randomized, single-blind study comparing a single doses of oral
         <sup>
          32P
         </sup>
         (12 mCi) and intravenous
         <sup>
          89
         </sup>
         Sr (4 mCi). Patients were well-matched in terms of tumor type, degree of osseous involvement, and pretreatment pain scores. Partial (&gt;50%) and complete (100%) analgesia responses were as follows:
         <sup>
          89
         </sup>
         Sr: 7/15 and 8/15 patients, respectively;
         <sup>
          32
         </sup>
         P: 7/16 and 7/16 patients, respectively. There were no significant differences in onset/duration/degree of analgesia or functional improvement. Hematologic toxicity was comparable save except that the
         <sup>
          32
         </sup>
         P group had more thrombocytopenia.
        </p>
        <p>
         <b>
          References
         </b>
        </p>
        <ol>
         <li>
          Hellman RS, Krasnow AZ. Radionuclide therapy for palliative of pain due to osteoblastic metastases. J Pall Med. 1998; 1:277-283.
         </li>
         <li>
          Silberstein EB. Painful osteoblastic metastases: the role of nuclear medicine. Oncology. 2001; 15(2):157-163.
         </li>
         <li>
          Lewington VJ. A practical guide to targeted therapy for bone pain palliation. Nucl Med Commun. 2002; 23(9):833-836.
         </li>
         <li>
          Mertens WC, Filipczak LA, Ben-Josef E, Davis LP, Porter AT. Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. CA Cancer J Clin.1998; 48(6):361-374.
         </li>
         <li>
          Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med. 1999; 40(2):256-261.
         </li>
        </ol>
        <p>
         <br/>
         <b>
          Fast Facts and Concepts
         </b>
         are edited by Drew A Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For more information write to:
         <a href="mailto:www.drosiell@mcw.edu?subject=EPERC%20Fast%20Facts%20and%20Concepts%20" linktype="5" target="_self">
          drosiell@mcw.edu
         </a>
         . More information, as well as the complete set of Fast Facts, are available at EPERC:
         <a href="http://www.eperc.mcw.edu" linktype="3" target="_blank">
          www.eperc.mcw.edu
         </a>
         .
        </p>
        <p>
         <b>
          Version History:
         </b>
         This Fast Fact was originally edited by David E Weissman MD and published in June 2004. Re-copy-edited in April 2009.
        </p>
        <p>
         <b>
          Copyright/Referencing Information:
         </b>
         Users are free to download and distribute Fast Facts for educational purposes only. Reisfield GM, Wilson GR. Radiopharmaceuticals for Painful Osseous Metastases. Fast Facts and Concepts. June 2004; 116. Available at:
         <a href="http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_116.htm">
          http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_116.htm
         </a>
         .
        </p>
        <p>
         <b>
          Disclaimer:
         </b>
         Fast Facts and Concepts provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.
        </p>
        <p>
         <b>
          ACGME Competencies:
         </b>
         Medical Knowledge, Patient Care
        </p>
        <p>
         <b>
          Keyword(s):
         </b>
         Pain – Non-Opioids
        </p>
       </div>
      </div>
      <!--/centerZone -->
      <div id="rightZone">
      </div>
      <!--/rightZone -->
     </div>
     <!--/contentContainer -->
    </div>
    <!-- /contentArea -->
    <!--/bottomContainer -->
   </div>
   <!--/mainBody -->
   <input air="flowplayer.controls-air-3.2.12.swf" basedir="/display/components/Blocks/Freeform_CK/ckeditor/plugins/titanflowplayer/" id="flowPlayerSettings" js="flowplayer-3.2.11.min.js" modern="flowplayer.controls-3.2.12.swf" pseudo="flowplayer.pseudostreaming-3.2.9.swf" swf="flowplayer-3.2.12.swf" tube="flowplayer.controls-tube-3.2.12.swf" type="hidden"/>
  </form>
 </body>
</html>
